Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Expert Video Report on biomarkers for immune checkpoint blockade in patients with solid tumours - AACR 2022

Reporting onsite from AACR 2022 in New Orleans, Benoit Rousseau reviews the results from a study looking at the occurrence of POLE defects to predict the activity of nivolumab in solid tumours, and to specify the range of TMB application as a biomarker for immune checkpoint blockade. He further reviews the CheckMate 848 results comparing nivo+ipi vs nivo alone in metastatic solid tumours with high TMB, supporting the predictive value of TMB rather from tumour rather than from blood samples.


  • CT021 - PD-1 blockade in solid tumors with defects in polymerase epsilon - Benoît Rousseau, et al.
  • CT022 - CheckMate 848: A randomized, open-label, phase 2 study of nivolumab in combination with ipilimumab or nivolumab monotherapy in patients with advanced or metastatic solid tumors of high tumor mutational burden - Michael Schenker, et al.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.